title: Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group.
abstract: OBJECTIVE
  To assess the response rate, survival, and toxicity of Taxol (paclitaxel) as 1-h infusion plus doxorubicin as first-line treatment for patients with metastatic breast cancer (MBC).
  
  
  METHODS
  Seventy-six patients with untreated MBC were recruited. All of them had measurable disease and were evaluable for toxicity. Fifty-five percent of the patients had visceral involvement. The dose of doxorubicin was fixed at 50 mg/m2 as a short intravenous infusion, followed by 200 mg/m2 of Taxol as a 1-h intravenous infusion. Doxorubicin was administered during the first seven cycles, continuing with Taxol only up to a maximum of ten cycles.
  
  
  RESULTS
  Neutropenia was the most important toxicity: 30% grade 3 and 18% grade 4. Only 2 patients showed a decrease in the left ventricular ejection fraction (LVEF) which caused discontinuing the treatment. No clinical congestive heart failure (CHF) was observed. Seventy-four patients were eligible for response evaluation: 10 (14%) achieved complete response (CR) and 46 (62%) achieved partial response (PR). The mean duration of response was 13.47+/-1.35 months (95% confidence interval (CI): 10.82; 16.12) and the mean survival was 21.50+/-1.42 months (95% CI: 18.72; 24.29).
  
  
  CONCLUSIONS
  The overall response (OR) rate was 76%. No CHF was assessed and 2 patients stopped treatment due to LVEF decrease. Although doxorubicin 50 mg/m2 followed by Taxol 200 mg/m2 in 1-h intravenous infusion presents a toxicity profile which demands a close follow-up, it represents a convenient outpatient schedule with similar activity rate compared to longer Taxol infusions.
authors.forename: C
authors.initials: C
authors.lastname: Pazos
authors.forename: E
authors.initials: E
authors.lastname: Mickiewicz
authors.forename: M R
authors.initials: MR
authors.lastname: Di Notto
authors.forename: F
authors.initials: F
authors.lastname: Cóppola
authors.forename: M
authors.initials: M
authors.lastname: Ventriglia
authors.forename: S
authors.initials: S
authors.lastname: Jovtis
authors.forename: L
authors.initials: L
authors.lastname: Balbiani
authors.forename: D
authors.initials: D
authors.lastname: Lewi
authors.forename: M
authors.initials: M
authors.lastname: Róndinón
authors.forename: G
authors.initials: G
authors.lastname: Témperley
authors.forename: M
authors.initials: M
authors.lastname: Trigo
authors.forename: A M
authors.initials: AM
authors.lastname: Bertoncín
authors.forename: M
authors.initials: M
authors.lastname: Pascual
authors.forename: G
authors.initials: G
authors.lastname: Uranga
authors.forename: E
authors.initials: E
authors.lastname: Cazap
authors.forename: S
authors.initials: S
authors.lastname: Breier
authors.forename: S
authors.initials: S
authors.lastname: Grasso
authors.forename: R
authors.initials: R
authors.lastname: Estévez
authors.forename: E
authors.initials: E
authors.lastname: Triguboff
authors.forename: A
authors.initials: A
authors.lastname: Alvarez
authors.forename: A
authors.initials: A
authors.lastname: Suárez
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001118:Argentina; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D013318:Stroke Volume / Q000187:drug effects; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin; D017239:Paclitaxel